Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Non Operating Income (2022 - 2025)

Atara Biotherapeutics filings provide 4 years of Non Operating Income readings, the most recent being -$843000.0 for Q4 2025.

  • On a quarterly basis, Non Operating Income fell 847.19% to -$843000.0 in Q4 2025 year-over-year; TTM through Mar 2026 was -$1.6 million, a 395.78% decrease, with the full-year FY2025 number at -$3.1 million, down 695.27% from a year prior.
  • Non Operating Income hit -$843000.0 in Q4 2025 for Atara Biotherapeutics, down from $4000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $50.6 million in Q2 2022 to a low of -$843000.0 in Q4 2025.
  • Median Non Operating Income over the past 4 years was -$8000.0 (2023), compared with a mean of $3.1 million.
  • Biggest five-year swings in Non Operating Income: soared 2155.56% in 2024 and later plummeted 13350.0% in 2025.
  • Atara Biotherapeutics' Non Operating Income stood at $969000.0 in 2022, then tumbled by 86.69% to $129000.0 in 2023, then plummeted by 168.99% to -$89000.0 in 2024, then tumbled by 847.19% to -$843000.0 in 2025.
  • The last three reported values for Non Operating Income were -$843000.0 (Q4 2025), $4000.0 (Q3 2025), and -$807000.0 (Q2 2025) per Business Quant data.